development aspects – Page 2

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

7 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space

8 months ago talkbio0Tagged 5'-NUCLEOTIDASE, biotech, development aspects, I-Mab, sanofi, Strategic Options

I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development

Cyclacel Pharmaceuticals Seeks Financial Lifeline Amidst Cash Crunch

9 months ago talkbio0Tagged cancer medicine, Cyclacel, development aspects, Financial cost, Financial Stress, Nasdaq, Risk, strategic alternatives

Cyclacel Pharmaceuticals, financial challenges, cost reduction, strategic alternatives, Nasdaq delisting risk, cancer medicine development

Rona’s Sanofi-Sourced siRNA Demonstrates Early Efficacy in Dyslipidaemia Treatment

9 months ago talkbio0Tagged development aspects, Dyslipidemias, Interferes with, Lipid Metabolism Disorders, RNA, RNA, Small Interfering, Rona, sanofi

siRNA, dyslipidaemia, Rona, Sanofi, RNA interference, lipid disorders, therapeutic development

Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development

11 months ago talkbio0Tagged Cancer Vaccines, Chapter 11, Clinical Trials, development aspects, financial restructuring, Gritstone Bio, Immunotherapy, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.

Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research

11 months ago talkbio0Tagged Chapter 11, Clinical Research, Communicable Diseases, development aspects, Gritstone Bio, Neoplasms, strategic alternatives, Vaccines

Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases

BIOSECURE Act: Navigating Industry Implications and Future Directions

11 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience